Drug Overview
Singulair (montelukast; Merck & Co/Kyorin) is an oral leukotriene D4 receptor antagonist used for prophylactic treatment of asthma. The drug is available in several oral formulations and is primarily taken as an add-on therapy for patients with refractory and/or allergic asthma.
1 Product Profiles
List of Figures
Figure 1: Singulair for asthma - SWOT analysis
Figure 2: The author’s drug assessment summary of Singulair in asthma
Figure 3: The author’s drug assessment summary of Singulair in asthma
Figure 4: Singulair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Singulair drug profile
Table 2: Singulair pivotal trial data in asthma
Table 3: Singulair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Singulair (montelukast; Merck & Co/Kyorin) is an oral leukotriene D4 receptor antagonist used for prophylactic treatment of asthma. The drug is available in several oral formulations and is primarily taken as an add-on therapy for patients with refractory and/or allergic asthma.
1 Product Profiles
- Singulair: Asthma
List of Figures
Figure 1: Singulair for asthma - SWOT analysis
Figure 2: The author’s drug assessment summary of Singulair in asthma
Figure 3: The author’s drug assessment summary of Singulair in asthma
Figure 4: Singulair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Singulair drug profile
Table 2: Singulair pivotal trial data in asthma
Table 3: Singulair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Companies Mentioned
- Merck & Co
- Kyorin
